Bristol-Myers (BMY), AstraZeneca (AZN) SAVOR-TIMI-53 Misses Primary Efficacy Endpoint in Phase 4
Go back to Bristol-Myers (BMY), AstraZeneca (AZN) SAVOR-TIMI-53 Misses Primary Efficacy Endpoint in Phase 4| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 75.03 +3.83 (5.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $71.20 | 52 Week High | $35.04 | |||
| Open | $74.99 | 52 Week Low | $26.97 | |||
| Day High | $75.81 | P/E | N/A | |||
| Day Low | $74.50 | EPS | $0.00 | |||
| Volume | 15,711,345 | |||||
| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 44.70 -4.16 (8.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $48.86 | 52 Week High | $77.12 | |||
| Open | $47.39 | 52 Week Low | $49.03 | |||
| Day High | $47.50 | P/E | 29.03 | |||
| Day Low | $44.37 | EPS | $1.54 | |||
| Volume | 45,094,676 | |||||
